<DOC>
	<DOCNO>NCT00948090</DOCNO>
	<brief_summary>This study outcome safety individualize busulfan dose cyclophosphamide etoposide patient prepare stem cell transplant treat Non-Hodgkin Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>PK-directed Dose Adjustment IV Busulfan Conditioning Regimen Autologous Stem Cell Transplant Lymphoma Patients</brief_title>
	<detailed_description>Evaluation progression-free survival , transplant related mortality , overall survival , overall response rate , subject NHL HL receive IV busulfan-based condition regimen PK-guided IV busulfan dosing , follow autologous HSCT well comparison receive carmustine , etoposide , cytarabine , melphalan ( BEAM ) condition regimen ( variant ) obtain registry data Center International Blood Marrow Transplant Research ( CIBMTR ) Assessment safety profile BuCyE condition regimen PK-directed dose IV busulfan also complete .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Subjects NHL include : Any subject NHL relapse progress follow initial therapy anthracyclinebased chemotherapy regimen achieve subsequent partial remission ( PR ) complete remission ( CR ) follow salvage chemotherapy regimen . Any subject NHL initially refractory anthracyclinebased chemotherapy regimen achieve PR CR follow salvage chemotherapy regimen . Any subject initial International Prognostic Index ( IPI ) score 45 achieve PR CR follow anthracyclinebased chemotherapy regimen except subject Mantle cell , T cell Natural Killer ( NK ) cell pathology . Subjects Mantle cell , T cell NK cell lymphoma may enrol PR CR initial therapy . Any subject relapse progress follow previous autologous HSCT . Subjects HL include : Any subject HL relapse progress follow initial therapy multidrug chemotherapy regimen achieve subsequent PR CR follow salvage chemotherapy regimen . Any subject HL initially refractory multidrug chemotherapy regimen achieve PR CR follow salvage chemotherapy regimen . Any subject relapse progress follow previous autologous HSCT . Any subject chemoresistant disease demonstration less PR recent chemotherapy , subject prior treatment history autologous HSCT highdose chemotherapy stem cell rescue medical reason exclude . Excluded also subject exist active central nervous system lymphoma human immunodeficiency virus relate lymphoma , unacceptable organ function , uncontrolled infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Bone marrow transplant</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>busulfan</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>etoposide</keyword>
</DOC>